AXGT - Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences
- Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists
NEW YORK and BASEL, Switzerland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the company will provide a corporate overview and participate in 1:1 meetings at upcoming virtual investor and patient conferences in September. Additionally, the company announced plans for their 1st Parkinson’s Disease R&D Day with key opinion leaders.
Investor and Patient Conference Presentation details:
| Baird Global Healthcare Conference |
| Date: |
| Wednesday, September 9, 2020 |
| Time: |
| 9:40 AM ET |
| 2020 Virtual GM1 Family Meeting |
| Date: |
| Thursday, September 10, 2020 |
| Time: |
| 6:45 PM ET |
| Registration Link: |
| https://curegm1.org/2020-gm1-family-meeting-san-francisco/ |
| Cantor Fitzgerald Virtual Global Healthcare Conference |
| Date: |
| Thursday, September 17, 2020 |
| Time: |
| 1:20 PM ET |
| Webcast link: |
| https://www.webcaster4.com/Webcast/Page/2495/37417 |
| 20th Annual Biotech in Europe Forum |
| Date: |
| Thursday, September 24, 2020 |
| Time: |
| 9:00 AM ET |
| Registration link: |
| https://www.sachsforum.com/20bef-registration.html |
| AXO-Lenti-PD Parkinson’s Disease R&D Day |
| Date: |
| Friday, October 30, 2020 |
| Moderator: |
| Gavin Corcoran, MD, Chief R&D Officer, Axovant Gene Therapies |
| Additional details to be provided later in September. |
A live webcast of the presentations will be available in the Events section of Axovant's website at www.axovant.com. A replay will be available for approximately 30 days following the conference.
About Axovant Gene Therapies
Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com.
Contacts:
Media & Investors
Parag Meswani
Axovant Gene Therapies Ltd.
(212) 547-2523
media@axovant.com
investors@axovant.com
Source: Axovant Gene Therapies